TD Cowen adjusted its financial outlook for ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology, and medical device industries.
Analyst Michael Cherny from Leerink Partners reiterated a Buy rating on Icon (ICLR – Research Report) and decreased the price target to $245.00 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback